selective cox-2 inhibitors

41
Selective COX-2 Selective COX-2 Inhibitors Inhibitors

Upload: porter-riggs

Post on 31-Dec-2015

48 views

Category:

Documents


2 download

DESCRIPTION

Selective COX-2 Inhibitors. Pharmacology of Selective COX-2 Inhibitors (COXIBs). Discovery in early 1990: cyclo-oxygenase (COX) existed in 2 distinct isoforms While COX-1 and COX-2 are structurally similar COX-2 contains a side pocket. Pharmacology of Selective COX-2 Inhibitors (COXIBs). - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Selective COX-2 Inhibitors

Selective COX-2 Selective COX-2 InhibitorsInhibitors

Page 2: Selective COX-2 Inhibitors

Pharmacology of Pharmacology of Selective COX-2 Inhibitors Selective COX-2 Inhibitors

(COXIBs)(COXIBs)

Discovery in early 1990: cyclo-Discovery in early 1990: cyclo-oxygenase (COX) existed in 2 distinct oxygenase (COX) existed in 2 distinct isoforms isoforms

While COX-1 and COX-2 are While COX-1 and COX-2 are structurally similarstructurally similar

COX-2 contains a side pocketCOX-2 contains a side pocket

Page 3: Selective COX-2 Inhibitors

Pharmacology of Pharmacology of Selective COX-2 Inhibitors Selective COX-2 Inhibitors

(COXIBs)(COXIBs)

Page 4: Selective COX-2 Inhibitors

Pharmacology of Pharmacology of Selective COX-2 Inhibitors (COXIBs)Selective COX-2 Inhibitors (COXIBs)

Page 5: Selective COX-2 Inhibitors

Pharmacology of Pharmacology of Selective COX-2 Inhibitors Selective COX-2 Inhibitors

(COXIBs)(COXIBs) Ratio of affinities to COX-1 and COX-Ratio of affinities to COX-1 and COX-

2 determines how “selective” 2 determines how “selective” a a compound iscompound is

NSAIDs inhibit COX-1 and COX-2 with NSAIDs inhibit COX-1 and COX-2 with different ratiosdifferent ratios

Differences in selectivity lead to Differences in selectivity lead to some variability in some variability in Clinical action Clinical action Safety profilesSafety profiles

Page 6: Selective COX-2 Inhibitors

Classification and Classification and Basic Differences of COXIBsBasic Differences of COXIBs

ClassificationClassification DrugDrug SelectivitySelectivity Chemical Chemical structurestructure

First First generationgeneration

CelecoxibCelecoxib

RofecoxibRofecoxib3030

272272SulfonamideSulfonamide

SulfoneSulfone

Second Second generationgeneration

ValdecoxibValdecoxib

EtoricoxibEtoricoxib

LumiracoxibLumiracoxib

6161

344344

433433

SulfonamideSulfonamide

SulfoneSulfonePhenylacetic Phenylacetic acid derivativeacid derivative

Page 7: Selective COX-2 Inhibitors

COX-1 vs COX-COX-1 vs COX-22

Page 8: Selective COX-2 Inhibitors

Cyclo-oxygenase I (COX-Cyclo-oxygenase I (COX-1)1)

Constitutive enzymeConstitutive enzyme

““House keeping” enzymeHouse keeping” enzyme

Expresses ubiquitouslyExpresses ubiquitously

Mediates physiological responsesMediates physiological responses

Page 9: Selective COX-2 Inhibitors

Cyclo-oxygenase I (COX-Cyclo-oxygenase I (COX-1)1)

Only isoenzyme found in plateletsOnly isoenzyme found in platelets

Thromboxane AThromboxane A22 (TXA (TXA22) formation) formation

Also plays a role inAlso plays a role in

Protection of GI mucosaProtection of GI mucosa

Renal hemodynamicsRenal hemodynamics

Platelet thrombogenesis Platelet thrombogenesis

Page 10: Selective COX-2 Inhibitors

Cyclo-oxygenase II (COX-Cyclo-oxygenase II (COX-22))

Highly expressed by cells Highly expressed by cells involved in inflammationinvolved in inflammation (eg. (eg. macrophage, monocytes, synoviocytes)macrophage, monocytes, synoviocytes)

Unregulated by bacterial Unregulated by bacterial lipopolysaccharides, cytokines, lipopolysaccharides, cytokines, growth factors, tumor promotersgrowth factors, tumor promoters

Page 11: Selective COX-2 Inhibitors

Cyclo-oxygenase II (COX-Cyclo-oxygenase II (COX-2)2)

““Inducible” formInducible” form

Primarily responsible for Primarily responsible for synthesis of prostanoids involved synthesis of prostanoids involved in acute and chronic in acute and chronic inflammatory states inflammatory states

Page 12: Selective COX-2 Inhibitors
Page 13: Selective COX-2 Inhibitors

COX-1 and COX-2COX-1 and COX-2

However, this distinction is somewhat However, this distinction is somewhat simplifiedsimplified

COX-2 also constitutively expressed under COX-2 also constitutively expressed under physiological conditions in severe tissues physiological conditions in severe tissues Brain Brain Spinal cordSpinal cord KidneyKidney Vascular endotheliumVascular endothelium

COX-1 also be unregulated to a certain COX-1 also be unregulated to a certain degree in inflammationdegree in inflammation

Page 14: Selective COX-2 Inhibitors

Development of Development of COXIBsCOXIBs

Page 15: Selective COX-2 Inhibitors

Development of COXIBSDevelopment of COXIBS

Theoretically, selective inhibition Theoretically, selective inhibition of COX-2 would provideof COX-2 would provide

Anti-inflammatory effectsAnti-inflammatory effects

Without disrupting gastric Without disrupting gastric cytoprotection and platelet cytoprotection and platelet functionfunction

Page 16: Selective COX-2 Inhibitors

Development of COXIBSDevelopment of COXIBS

Hypothesis: selective inhibition Hypothesis: selective inhibition of COX-2 will haveof COX-2 will have

Therapeutic actions similar to Therapeutic actions similar to NSAIDsNSAIDs

Without GI side effectsWithout GI side effects

Page 17: Selective COX-2 Inhibitors

Thromboxane AThromboxane A22 (TXA (TXA22) ) & &

Prostacyclin (PGIProstacyclin (PGI22))

Page 18: Selective COX-2 Inhibitors

Thromboxane AThromboxane A2 2 (TXA(TXA22))

Synthesized by COX-1 in plateletSynthesized by COX-1 in platelet VasoconstrictionVasoconstriction Smooth muscle proliferationSmooth muscle proliferation Platelet aggregationPlatelet aggregation

Page 19: Selective COX-2 Inhibitors

Prostacyclin (PGIProstacyclin (PGI22))

In contrast, PGIIn contrast, PGI22, a product of , a product of arachidonic acid (AA) from COX-2 in arachidonic acid (AA) from COX-2 in vessel walls plays important role in vessel walls plays important role in homeostatic defense mechanism homeostatic defense mechanism that promotesthat promotes

VasodilatationVasodilatation

Inhibition of platelet functionInhibition of platelet function

Page 20: Selective COX-2 Inhibitors

NSAIDS and COXIBsNSAIDS and COXIBs NSAIDs block both COX-1 and COX-2 NSAIDs block both COX-1 and COX-2

production to a similar extentproduction to a similar extent

In contrast, COXIBs inhibits PGIIn contrast, COXIBs inhibits PGI22 productionproduction

Thus, COXIBs may create an imbalance Thus, COXIBs may create an imbalance between TXAbetween TXA22 and PGI and PGI22

This might be the dominant mechanism This might be the dominant mechanism that can lead to increased risk of that can lead to increased risk of thrombosisthrombosis

Page 21: Selective COX-2 Inhibitors
Page 22: Selective COX-2 Inhibitors

Therapeutic Therapeutic UseUse

Page 23: Selective COX-2 Inhibitors

Therapeutic UseTherapeutic Use

Postoperative painPostoperative pain Osteoarthritis (OA)Osteoarthritis (OA) Rheumatoid arthritis (RA)Rheumatoid arthritis (RA) Acute gouty arthritisAcute gouty arthritis Chemoprevention Chemoprevention

Its role in carcinogenesis, apoptosis and Its role in carcinogenesis, apoptosis and angiogenesisangiogenesis

Celecoxib approved for Rx of familial Celecoxib approved for Rx of familial adenomatous polyp (FAP)adenomatous polyp (FAP)

Page 24: Selective COX-2 Inhibitors

Clinical Clinical SafetySafety

Page 25: Selective COX-2 Inhibitors

Gastrointestinal Gastrointestinal

(GI) Tract(GI) Tract

Page 26: Selective COX-2 Inhibitors

Gastrointestinal (GI) TractGastrointestinal (GI) Tract

Common reported adverse events Common reported adverse events (AEs) were related to GI tract(AEs) were related to GI tract

DyspepsiaDyspepsia

DiarrheaDiarrhea

NauseaNausea

Abdominal painAbdominal pain

FlatulenceFlatulence

Page 27: Selective COX-2 Inhibitors

Gastrointestinal (GI) TractGastrointestinal (GI) Tract

Upper GI complications have also Upper GI complications have also occurred in pts treated with occurred in pts treated with COXIBsCOXIBs

PerforationPerforation

UlcersUlcers

BleedingsBleedings

PUBsPUBs

Page 28: Selective COX-2 Inhibitors

Gastrointestinal (GI) TractGastrointestinal (GI) Tract

Many large RCTsMany large RCTs COXIBs caused COXIBs caused

fewer GI AEs fewer GI AEs compared to NSAIDscompared to NSAIDs

However, most, if However, most, if not all, of the GI not all, of the GI benefits will be lost benefits will be lost in pts who take in pts who take low-dose aspirinlow-dose aspirin

Page 29: Selective COX-2 Inhibitors

Cardiovascular Cardiovascular (CV) System(CV) System

Page 30: Selective COX-2 Inhibitors

Cardiovascular (CV) Cardiovascular (CV) SystemSystem

First evidence that COXIBs might First evidence that COXIBs might increase CV risk emerged from increase CV risk emerged from VIGOR studyVIGOR study

Rofecoxib group: 5-fold increase in Rofecoxib group: 5-fold increase in thromboembolic events (primarily thromboembolic events (primarily

acute MIacute MI) )

Page 31: Selective COX-2 Inhibitors

KidneyKidney

Page 32: Selective COX-2 Inhibitors

KidneyKidney

COX-2 also constitutively expressed COX-2 also constitutively expressed

in kidneyin kidney

Is regulated in response to alterations Is regulated in response to alterations in intravascular volume in intravascular volume

COXIBs may transiently COXIBs may transiently Decrease urinary NaDecrease urinary Na++ excretion excretion Can induce mild to moderate BP Can induce mild to moderate BP

elevationelevation

Page 33: Selective COX-2 Inhibitors

COXIBs and NSAIDs COXIBs and NSAIDs

Similar effects for kidney damageSimilar effects for kidney damage Renal insufficiencyRenal insufficiency

NaNa++ retention with HT retention with HT

Peripheral edemaPeripheral edema

HyperkalemiaHyperkalemia

Papillary necrosisPapillary necrosis

KidneyKidney

Page 34: Selective COX-2 Inhibitors

Other Adverse Other Adverse Events (AEs)Events (AEs)

Page 35: Selective COX-2 Inhibitors

Other (Common) Adverse Other (Common) Adverse EventsEvents

DizzinessDizziness

HeadacheHeadache

Flu-like symptomsFlu-like symptoms

FatigueFatigue

AnxietyAnxiety

InsomniaInsomnia

Page 36: Selective COX-2 Inhibitors

Other Adverse EventsOther Adverse Events

As a sulfonamide, celecoxib can cause As a sulfonamide, celecoxib can cause cutaneous adverse reactions without cutaneous adverse reactions without warning even in pts with no history of warning even in pts with no history of sulfonamide allergysulfonamide allergy RashRash UrticariaUrticaria Photoallergic dermatitisPhotoallergic dermatitis Serious and potentially fetal AEsSerious and potentially fetal AEs

Exfoliative dermatitisExfoliative dermatitis Steven Johnson syndromeSteven Johnson syndrome Toxic epidermal necrolysisToxic epidermal necrolysis

Page 37: Selective COX-2 Inhibitors

Other Adverse EventsOther Adverse Events

Etoricoxib 30-90 mg/day for up to 1 yr, Etoricoxib 30-90 mg/day for up to 1 yr, the most frequently reported lab AEsthe most frequently reported lab AEs Increased level of SGOTIncreased level of SGOT Increased level of SGPTIncreased level of SGPT 1-2.1%1-2.1%

Hepatic dysfunction presents a Hepatic dysfunction presents a contraindicationcontraindication

During long-term Rx with COXIBs, LFTs During long-term Rx with COXIBs, LFTs should be regularly monitoredshould be regularly monitored

Page 38: Selective COX-2 Inhibitors

Other Adverse EventsOther Adverse Events

Lumiracoxib withdrawn due to Lumiracoxib withdrawn due to severe liver damagesevere liver damage

Page 39: Selective COX-2 Inhibitors

ConclusionsConclusions

Page 40: Selective COX-2 Inhibitors

ConclusionsConclusions

CV risks of COXIBs apparently CV risks of COXIBs apparently increase with increase with dosedose and and durationduration of of exposureexposure

If COXIBs indicatedIf COXIBs indicated The lowest effective doseThe lowest effective dose For a limited timeFor a limited time

BPBP as well as as well as renalrenal and and hepatic hepatic functionfunction advisably monitored advisably monitored

Page 41: Selective COX-2 Inhibitors

ConclusionsConclusions

COXIBs should not be prescribed in COXIBs should not be prescribed in pts withpts with

Ischemic heart diseaseIschemic heart disease

Cerebrovascular disorders (stroke)Cerebrovascular disorders (stroke)

Peripheral arterial diseasePeripheral arterial disease